Luminex Corporation (NASDAQ:LMNX) – Jefferies Group raised their Q1 2018 earnings estimates for Luminex Corporation in a report released on Friday. Jefferies Group analyst B. Couillard now expects that the medical instruments supplier will earn $0.17 per share for the quarter, up from their previous estimate of $0.13. Jefferies Group currently has a “Hold” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Luminex Corporation’s Q2 2018 earnings at $0.15 EPS, Q3 2018 earnings at $0.15 EPS and Q4 2018 earnings at $0.16 EPS.

Luminex Corporation (NASDAQ:LMNX) last issued its earnings results on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.11. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The business had revenue of $76.50 million during the quarter, compared to analysts’ expectations of $75.45 million. During the same quarter in the previous year, the business earned $0.33 EPS. The company’s revenue for the quarter was up 19.2% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: “Jefferies Group Weighs in on Luminex Corporation’s Q1 2018 Earnings (LMNX)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/jefferies-group-weighs-in-on-luminex-corporations-q1-2018-earnings-lmnx.html.

Other equities analysts have also issued research reports about the company. Zacks Investment Research upgraded Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Monday, July 17th. TheStreet lowered Luminex Corporation from a “b” rating to a “c+” rating in a research note on Monday, August 7th. ValuEngine upgraded Luminex Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, BidaskClub lowered Luminex Corporation from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a strong buy rating to the stock. Luminex Corporation has an average rating of “Hold” and an average price target of $20.00.

Shares of Luminex Corporation (NASDAQ:LMNX) opened at 20.46 on Monday. The stock’s 50 day moving average price is $20.07 and its 200-day moving average price is $20.05. Luminex Corporation has a one year low of $17.64 and a one year high of $22.27. The stock has a market cap of $901.69 million, a PE ratio of 63.34 and a beta of 0.29.

The business also recently declared a quarterly dividend, which was paid on Friday, October 13th. Investors of record on Friday, September 22nd were given a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend was Thursday, September 21st. Luminex Corporation’s dividend payout ratio is currently 75.00%.

In related news, Director Robert J. Cresci sold 19,631 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total transaction of $372,596.38. Following the sale, the director now owns 260,358 shares of the company’s stock, valued at $4,941,594.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.90% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Mason Street Advisors LLC grew its position in Luminex Corporation by 0.5% during the first quarter. Mason Street Advisors LLC now owns 8,713 shares of the medical instruments supplier’s stock worth $160,000 after buying an additional 46 shares in the last quarter. McQueen Ball & Associates Inc. grew its position in Luminex Corporation by 0.3% during the second quarter. McQueen Ball & Associates Inc. now owns 29,095 shares of the medical instruments supplier’s stock worth $614,000 after buying an additional 95 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Luminex Corporation by 1.3% during the second quarter. The Manufacturers Life Insurance Company now owns 31,640 shares of the medical instruments supplier’s stock worth $668,000 after buying an additional 402 shares in the last quarter. Pinebridge Investments L.P. grew its position in Luminex Corporation by 8.3% during the second quarter. Pinebridge Investments L.P. now owns 5,266 shares of the medical instruments supplier’s stock worth $111,000 after buying an additional 405 shares in the last quarter. Finally, Sei Investments Co. grew its position in Luminex Corporation by 10.9% during the first quarter. Sei Investments Co. now owns 5,946 shares of the medical instruments supplier’s stock worth $110,000 after buying an additional 582 shares in the last quarter. 78.12% of the stock is currently owned by institutional investors and hedge funds.

Luminex Corporation Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Earnings History and Estimates for Luminex Corporation (NASDAQ:LMNX)

Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.